Pharmacovigilance - mRNA COVID-19 vaccines : current state of knowledge on their adverse effects
The COVID-19 pandemic has stimulated the rapid development and large-scale use of technologically innovative vaccines, such as the mRNA vaccines Spikevax (Moderna) and Comirnaty (Pfizer-BioNTech). This unprecedented deployment has challenged pharmacovigilance, requiring combined skills in safety monitoring, prompt data analysis and continuous dissemination of knowledge. Main recognised adverse events of these vaccines are moderate and transient, linked to their significant reactogenicity. Active post-marketing surveillance has identified rare adverse events such as myopericarditis and a variety of skin reactions. A number of potential rare adverse events are being evaluated and could be retained at the individual level, but do not question the overall safety of these vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 18(2022), 767 vom: 02. Feb., Seite 190-197 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Pharmacovigilance - Vaccins à ARNm contre le Covid-19 : le point sur les effets indésirables |
|---|
| Beteiligte Personen: |
Favre, Valérie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.02.2022 Date Revised 04.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2022.18.767.190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336414684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336414684 | ||
| 003 | DE-627 | ||
| 005 | 20231225232107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2022.18.767.190 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336414684 | ||
| 035 | |a (NLM)35107895 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Favre, Valérie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacovigilance - mRNA COVID-19 vaccines |b current state of knowledge on their adverse effects |
| 246 | 3 | 3 | |a Pharmacovigilance - Vaccins à ARNm contre le Covid-19 : le point sur les effets indésirables |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2022 | ||
| 500 | |a Date Revised 04.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The COVID-19 pandemic has stimulated the rapid development and large-scale use of technologically innovative vaccines, such as the mRNA vaccines Spikevax (Moderna) and Comirnaty (Pfizer-BioNTech). This unprecedented deployment has challenged pharmacovigilance, requiring combined skills in safety monitoring, prompt data analysis and continuous dissemination of knowledge. Main recognised adverse events of these vaccines are moderate and transient, linked to their significant reactogenicity. Active post-marketing surveillance has identified rare adverse events such as myopericarditis and a variety of skin reactions. A number of potential rare adverse events are being evaluated and could be retained at the individual level, but do not question the overall safety of these vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Ekobena, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Chtioui, Haithem |e verfasserin |4 aut | |
| 700 | 1 | |a Rothuizen, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Livio, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Genton, Blaise |e verfasserin |4 aut | |
| 700 | 1 | |a Buclin, Thierry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 18(2022), 767 vom: 02. Feb., Seite 190-197 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:767 |g day:02 |g month:02 |g pages:190-197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2022.18.767.190 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 767 |b 02 |c 02 |h 190-197 | ||